Clinicopathological study of Japanese patients with genetic iron overload syndromes

Pathology International

Volumn 62, Issue 9, 2012, Pages 612-618

  Hattori, Ai ^a,b   Miyajima, Hiroaki ^c   Tomosugi, Naohisa ^d   Tatsumi, Yasuaki ^b   Hayashi, Hisao ^b   Wakusawa, Shinya ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aceruloplasminemia; Ferroportin; Hemochromatosis; Hepcidin

Indexed keywords

FERROPORTIN; HEPCIDIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENETIC DISORDER; GENOTYPE; HEMOCHROMATOSIS; HUMAN; IRON METABOLISM; IRON METABOLISM DISORDER; IRON OVERLOAD; JAPANESE; KUPFFER CELL; LIVER FIBROSIS; LIVER PARENCHYMA; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; ASIAN CONTINENTAL ANCESTRY GROUP; CATION TRANSPORT PROTEINS; CERULOPLASMIN; FEMALE; GENETIC MARKERS; GENOTYPE; HEMOCHROMATOSIS; HEPCIDINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON OVERLOAD; JAPAN; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTORS, TRANSFERRIN; SYNDROME;

EID: 84865536442     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2012.02848.x     Document Type: Article

References (31)

1. Feder JN, Gnirke A, Thomas W etal. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
2. Beutler E, Gelbart T, West C etal. Mutation analysis in hereditary hemochromatosis. Blood Cell Mol Dis 1996; 22: 187-94.
3. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-8.
4. Camaschella C, Roetto A, Cali A etal. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-5.
5. Roetto A, Papanikolaou G, Politou M etal. Mutant antimicrobial hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-2.
6. Papanikolaou G, Samuels ME, Ludwig EH etal. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
7. Hattori A, Wakusawa S, Hayashi H etal. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003; 26: 154-6.
8. Koyama C, Hayashi H, Wakusawa S etal. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol 2005; 43: 740-2.
9. Bridle KR, Frazer DM, Wilkins SJ etal. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron hemeostasis. Lancet 2003; 361: 669-73.
10. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin decreased in TFR2 hemochromatosis. Blood 2005; 105: 1803-6.
11. Njajou OT, Vaessen N, Joosse M etal. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213-4.
12. Kaneko Y, Miyajima H, Piperno A etal. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 2010; 45: 1163-71.
13. Drakesmith H, Schimanski LM, Ormerod E etal. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106: 1092-7.
14. Letocart E, Le Gac G, Majore S etal. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009; 147: 379-85.
15. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761-7.
16. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007; 21: 4033-8.
17. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
18. Deugnier YM, Turlin B, Powell LW etal. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: A study of 192 cases. Hepatology 1993; 17: 30-4.
19. Fujita J, Inagaki Y, Yonei Y etal. A Japanese case of idiopathic hemochromatosis with analysis of HFE gene mutations and a review of literature on HLA phenotypes in the Japanese cases [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 2000; 97: 472-7.
20. Hachiya M, Watanabe H, Tsukimoto I, Fujisawa T. Hereditary hemochromatosis not associated with common HFE gene mutation in Japanese siblings. J Pediatr Gastroenterol Nutr 2001; 32: 501-3.
21. Koyama C, Wakusawa S, Hayashi H etal. Two novel mutations, L490R and V561X, in the transferrin receptor 2 in Japanese patients with hemochromatosis. Haematologica 2005; 90: 302-7.
22. Koyama C, Wakusawa S, Hayashi H etal. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: Hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med 2005; 44: 990-3.
23. Watanabe M, Asai C, Ishikawa K etal. Central diabetes inspidus and hypothalamic hypothyroidism associated with aceruloplasminemia. Intern Med 2010; 40: 1581-5.
24. Maeda T, Nakamaki T, Saito B etal. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: Improvement of liver disease activity, cardiac and hematological function. Eur J Haematol 2011; 87: 467-569.
25. Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ. Effect of iron overload on glucose metabolsim in patients with hereditary hemochromatosis. Metabolism 2010; 59: 380-4.
26. Ramm GA, Ruddell RG. Iron homeostasis, hepatocellular injury, and fibrogenesis in hemochromatosis: The role of inflammation in a noninflammatory liver disease. Semin Liver Dis 2010; 30: 271-87.
27. Hayashi H, Piperno A, Tomosugi N etal. Patients with chronic hepatitis C may be more sensitive to iron hepatotoxicity than patients with HFE-hemochromatosis. Intern Med 2010; 49: 2371-7.
28. Van der ADL, Rovers MM, Grobbee DE etal. Mutations in the HFE gene and cardiovascular disease risk: An individual patient data meta-analysis of 53880 subjects. Circ Cardiovasc Genet 2008; 1: 43-50.
29. Dunn T, Blankenship P, Deal N etal. HFE mutations in heart disease. Heart Vessels 2008; 23: 348-55.
30. Paro Silva MC, Njajou OT, Alizadeh BZ etal. HFE gene mutations increase the risk of coronary heart disease in women. Eur J Epidemiol 2010; 25: 643-9.
31. Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR. Acerulopasminemia with progressive atrophy without brain iron overload: Treatment with oral chelation. J Neurol Neurosurg Psychiatry 2008; 79: 467-70.